Sat.Mar 16, 2024 - Fri.Mar 22, 2024

article thumbnail

Study: Researchers Identify 25 Air Pollutants Associated With Asthma Symptoms

Pharmacy Times

Investigators found that 1,1,1 trichloroethane; 2-nitropropane; and 2,4,6 trichlorophenol were significantly associated with asthma symptoms for 3 exposure periods.

144
144
article thumbnail

Efficacy of Tapinarof Cream 1% Demonstrated in Atopic Dermatitis in Skin of Color

Drug Topics

A lack of diversity in clinical trials has hampered health care providers from understanding the nuances of diseases across specific patient populations.

98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The latest twist in John Green’s anti-tuberculosis story: working with governments

STAT

WASHINGTON — John Green, the popular novelist and YouTube star, gave the health care world a taste of his clout last year when he and his “Nerdfighter” fan base pressured corporations to cut prices for tuberculosis treatment. This week, he announced a more collaborative strategy for fighting tuberculosis — a public-private funding partnership with USAID and the Philippines.

133
133
article thumbnail

CAR-Ts set to move earlier in multiple myeloma therapy

pharmaphorum

FDA advisors have said that two BCMA-targeted CAR-T therapies can be used earlier in the treatment pathway for multiple myeloma, setting up FDA approvals for use in a broader patient population.

FDA 104
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

South Africans take on big pharma for access to ‘miracle’ cystic fibrosis drug

The Guardian - Pharmaceutical Industry

Cheri Nel cannot afford Vertex’s Trikafta medicine, so she is suing to end ‘patent abuse’ and allow a generic version Cheri Nel has a blunt message for the multibillion-dollar pharmaceutical company Vertex: “Any person that dies from today – that’s on you.” Vertex makes a “miracle drug” called Trikafta that can transform the lives of people with cystic fibrosis.

article thumbnail

A Pharmacy Consult with a Patient living with Bipolar I Disorder, Previously Using Oral Antipsychotics and Considering LAIs

Drug Topics

This video was sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. in collaboration with Lundbeck LLC.

98

More Trending

article thumbnail

FDA Advisory Committee Votes in Favor of Ide-Cel for Adult Patients With Multiple Myeloma

Pharmacy Times

The decision to vote in favor of idecabtagene vicleucel comes after positive phase 3 trial results demonstrating its efficacy compared with standard regimens.

FDA 65
article thumbnail

GSK shares data from phase 3 trial for Jemperli combinations for endometrial cancer treatment

Pharmafile

GSK has announced positive results from part 1 and part 2 of its RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial for Jemperli (dostarlimab) in combinations for the treatment of adult patients with primary advanced or recurrent endometrial cancer. The results demonstrated a statistically significant and clinically meaningful overall survival (OS) in part 1 and progression free survival (PFS) […] The post GSK shares data from phase 3 trial for Jemperli combinations for endometrial cancer treatment

64
article thumbnail

Hypertension Interventions Have Limited Success in Rural Black Populations

Drug Topics

Hypertension remains a significant problem in areas of the rural South.

98
article thumbnail

The harms of adverse childhood experiences are well-known. But positive experiences can affect future health, too

STAT

I was recently working with a young mother who struggled with depression and anxiety in the difficult year following the birth of her child. In addition to managing the herculean task of adjusting to motherhood, she had trouble coping with her baby’s complex medical needs. While I explained to her the importance of tending to her mental health and the connection between parental well-being and healthy child development, she burst out crying.

92
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

NCPA, Biosimilar Forum Voice Support for PBM Reform Bill

Pharmacy Times

Senators Ron Wyden and Mike Crapo reaffirm their support on 2 health care bills that passed the United States Senate Committee on Finance in 2023.

65
article thumbnail

Pfizer set to collect roughly $2.6B in selloff of Haleon shares, reducing stake from 32% to 24%

Fierce Pharma

Two months after GSK sold a significant chunk of its stake in Haleon, Pfizer is | Two months after GSK sold a significant chunk of its stake in Haleon, Pfizer is prepared to do the same with a larger selloff, according to the consumer healthcare company. Pfizer is set to reduce its stake in Haleon from 32% to 24% by selling 630 million shares in a public offering.

59
article thumbnail

A Pharmacy Consult with Patient with Bipolar 1 Considering Gluteal Injection of LAI

Drug Topics

This video was sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. in collaboration with Lundbeck LLC.

76
article thumbnail

STAT+: I was wrong about Geron’s blood cancer drug. Now, is it a takeover target?

STAT

I was wrong about Geron. For years, I’ve believed — and declared publicly — that Geron’s effort to develop a blood cancer drug called imetelstat would end in disappointment. The drug was never getting approved , I said. On Thursday, a group of outside experts convened by the Food and Drug Administration voted 12-2 in imetelstat’s favor, concluding the drug’s benefits outweighed its risks for the treatment of patients with myelodysplastic syndrome.

FDA 82
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Study Results Show Evolving DNA Methylation Can Help Understanding of Hematologic Diseases

Pharmacy Times

The authors note that understanding the DNA methylation profile in leukemia can help predict whether or not a patient will respond to treatment.

65
article thumbnail

Reading the Tea Leaves on Recent Surge in Pharma Dealmaking

Pharmaceutical Commerce

In this Pharmaceutical Commerce video interview, Joerg Tritschler, a partner in Simon-Kucher’s life sciences division, discusses the positive signs from rising activity levels in biopharma M&A— and what the momentum may mean for industry dealmaking and partnership efforts in the months ahead.

59
article thumbnail

AstraZeneca Caps Out-of-Pocket Inhaler Costs at $35 Per Month

Drug Topics

AstraZeneca is the second pharmaceutical company to cap out-of-pocket costs for eligible patients.

article thumbnail

STAT+: The Boston area built a ton of lab space. Now many of those buildings are opening empty

STAT

A round this time three years ago, while most of us   navigated pandemic life, real estate developers across Greater Boston looked to life-science laboratories, and saw dollar signs. The white-collar office workers who’d long filled downtown towers were largely staying home (unless they  worked in commercial real estate ). The future of cities had rarely been murkier.

94
article thumbnail

Promoting Nutrition Education and Sustainable Eating Practices for National Nutrition Month

Pharmacy Times

Laura Brown, MS, RDN, LDN, discusses the importance of National Nutrition Month, collaborating with pharmacists, promoting sustainable eating habits, and overcoming common nutrition misconceptions

81
article thumbnail

Merck shares results for Keytruda in cervical cancer treatment

Pharmafile

Merck, known as MSD outside of the US and Canada, has announced positive results from the phase 3 KEYNOTE-A18 trial, which investigates Keytruda in combination with chemoradiotherapy for the treatment of newly diagnosed patients with high-risk locally advanced cervical cancer. The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in […] The post Merck shares results for Keytruda in cervical cancer treatment appeared first on Pha

59
article thumbnail

Patient-centricity and HCP engagement: 7 Challenges in pharma and life sciences outreach

pharmaphorum

Discover the top 7 challenges faced by pharmaceutical and life sciences companies in achieving patient-centricity and engaging healthcare professionals (HCPs). Explore strategies to overcome these obstacles for successful outreach efforts.

59
article thumbnail

STAT+: Pharmalittle: We’re reading about CAR-T drugs for myeloma, CVS rebate credits, and more

STAT

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and inspiring, because that oh-so familiar routine of online meetings, phone calls, and deadlines has returned. You knew this would happen, yes? After all, the world, such as it is, continues to spin. So time to give it a nudge in a better direction with a cup of stimulation.

FDA 65
article thumbnail

Bacterial Load in Spinal Fluid Could Predict Pneumococcal Meningitis Outcomes

Pharmacy Times

High bacterial load in cerebrospinal fluid was associated with unfavorable outcomes and death for adults with pneumococcal meningitis.

65
article thumbnail

Small Doses: March 11 to March 15

Drug Topics

Check out a recap of important pharmacy news you might’ve missed this week, dispensed in small doses.

98
article thumbnail

Agreement reached on EU health data framework

pharmaphorum

Agreement has been reached in the EU on a European Health Data Space (EHDS), which will make it easier to exchange and access electronic health data.

64
article thumbnail

STAT+: As AI marches into medicine, investors eye security, privacy startups

STAT

Investors are starting to back startups that offer privacy and security services to bolster health AI products already on the market while they wait for crucial safety and privacy regulations to take shape. Though health leaders are racing to deploy generative AI products that can automatically transcribe doctor-patient conversations during medical appointments or churn through massive repositories of scientific research, they’re still flummoxed about how to measure their quality.

article thumbnail

BCMA-Targeting Therapies, Administration Routes Have Varying CRS Incidence and Severity in Patients With RRMM

Pharmacy Times

Chimeric antigen receptor T-cell therapies were associated with higher incidences, grades of severity, and longer duration of cytokine release syndrome compared with bispecific antibodies.

87
article thumbnail

AI’s Impact on CEO/Founder Sustainability

PharmExec

In this Pharmaceutical Executive video interview, Kaveh Vahdat, Founder and President of RiseOpp, discusses the impact AI will have on thelong-term well-being of founders and CEOs.

52
article thumbnail

NHS will expand use of waiting list-busting AI after pilot

pharmaphorum

AI software designed to tackle missed appointments and reduce waiting lists will see its use by NHS England ramp up after a successful pilot deployment.

59
article thumbnail

STAT+: FDA approves first gene therapy for a fatal neuron disease in children

STAT

The Food and Drug Administration on Monday approved a gene therapy for metachromatic leukodystrophy, a devastating genetic disorder that eats away at affected children’s neurons. The medicine, marketed as Lenmeldy, is the first treatment for MLD, which is otherwise fatal. Lenmeldy has to be given before symptoms appear or, in some cases, after the first signs of disease, so it won’t be helpful for many patients living with MLD today.

FDA 60
article thumbnail

Pharmacist Role in Addressing Operational Challenges of Bispecifics in MM

Pharmacy Times

Michael Singel, PharmD, discusses the role of pharmacists in the operationalization of bispecifics to treat multiple myeloma, including the creation of treatment plans and standard of care order sets.

65
article thumbnail

Does ibuprofen expire?

The Checkup by Singlecare

Maybe it’s the coffee you drink every morning. Or the yogurt that got pushed to the back of the fridge. Or a forgotten bunch of now-wilting spinach. Everything in the refrigerator and kitchen cabinets has an expiration date, and the medicine cabinet is no exception. The law requires all medications to have printed expiration dates, so the clock is ticking once you break the safety seal on ibuprofen.

article thumbnail

OS data set up wider Jemperli use in endometrial cancer

pharmaphorum

GSK's PD-1 inhibitor Jemperli improves overall survival when used first-line in an all-comer endometrial cancer trial

66
article thumbnail

Contineum Therapeutics files for IPO

STAT

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Today we ponder the vast open spaces of Boston’s unused life sciences labs, see a new biopharma IPO in the works, and expect a label expansion for some CAR-T blood cancer therapies.